7 Oversold Pharma Stocks to Buy Now

Industry Overview - The pharmaceutical sector in the United States was valued at $634.32 billion in 2024 and is projected to grow to $883.97 billion by 2030, driven primarily by customized medication, which is expected to increase from $169.56 billion in 2024 to $307.04 billion by 2033 at a CAGR of 6.82% [2] - The industry has undergone significant changes due to policy shifts during Donald Trump's administration, including a "Build It Here" campaign to boost domestic manufacturing and a 100% tariff on imported brand-name medications [3] - Regulatory reforms have expedited the approval of generic and biosimilar products, contributing to a larger movement toward cost containment and pharmaceutical self-sufficiency [3] Market Challenges - The pharmaceutical industry faces risks such as the impending $350 billion global patent cliff due to the loss of market exclusivity for key medications like Keytruda and Eliquis [4] - Despite these challenges, growth is expected to be sustained by advancements in gene treatments, biologics, and artificial intelligence [4] - Analysts from Deloitte, PwC, and S&P Global Ratings predict robust credit conditions supported by substantial cash reserves and ongoing industrial innovation [4] Company Highlights - Hims & Hers Health, Inc. (NYSE:HIMS) is identified as one of the most oversold stocks, with a Relative Strength Index (RSI) of 16.68 and a price target upside of 94.39% [9] - The company announced a deal to acquire Eucalyptus for up to $1.15 billion, with plans to finance the agreement through current cash and future U.S. operating cash flows [10][11] - Hims & Hers faced backlash after attempting to launch a $49 oral semaglutide weight-loss pill, leading to a quick reversal of the offering due to regulatory concerns [12] - Neurocrine Biosciences, Inc. (NASDAQ:NBIX) is another oversold stock with an RSI of 40.53 and a price target upside of 36.79% [14] - The company reported strong financial results, with Q4 net product sales increasing by 29% year-over-year to $798.3 million and full-year sales reaching $2.83 billion [15] - INGREZZA, one of Neurocrine's products, generated $657.5 million in Q4 sales, reflecting 7% annual growth, supported by strong prescription demand [16]